Selegiline transdermal system (STS) as an aid for smoking cessation

Nicotine and Tobacco Research

Volumn 14, Issue 3, 2012, Pages 377-382

  Kahn, Roberta ^a   Gorgon, Liza ^a   Jones, Karen ^b   McSherry, Frances ^b   Glover, Elbert D ^c   Anthenelli, Robert M ^d   Jackson, Thomas ^e   Williams, Jill ^f   Murtaugh, Cristin ^b   Montoya, Ivan ^a   Yu, Elmer ^g   Elkashef, Ahmed ^a  

^a Natonal Institute on Drug Abuse   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; PLACEBO; SELEGILINE;

APPLICATION SITE ERYTHEMA; ARTICLE; BREATH ANALYSIS; CLINICAL PRACTICE; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; TOBACCO DEPENDENCE;

EID: 84863229239     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntr143     Document Type: Article

References (21)

1. Berlin, I., Said, S., Spreux-Varoquaux, O., Launay, J. M., Olivares, R., Millet, V., et al. (1995). A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clinical Pharmacology and Therapeutics, 58, 444-452. doi:10.1016/0009-9236(95)90058-6.
2. Biberman, R., Neumann, R., Katzir, I., & Gerber, Y. (2003). A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction, 98, 1403-1407. doi:10.1046/j.1360-0443.2003.00524.x.
3. Cosgrove, K. P., Batis, J., Bois, F., Maciejewski, P. K., Esterlis, I., Kloczynski, M. A., et al. (2009). β2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Archives of General Psychiatry, 66, 666-676. Retrieved from http://archpsyc.ama-assn.org/cgi/content/full/66/6/666 (last accessed on 6/22/11).
4. Covey, L. S., Glassman, A. H., & Stetner, F. (1990). Depression and depressive symptoms in smoking cessation. Comprehensive Psychiatry, 31, 350-354. doi:10.1016/0010-440X(90)90042-Q.
5. Elkashef, A., Fudala, P. J., Gorgon, L., Li, S. H., Kahn, R., Chiang, N., et al. (2006). Double-blind placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug and Alcohol Dependence, 85, 191-197. doi:10.1016/j.drugalcdep.2006.04.010.
6. FDA. (1995). Transcript of the Joint Meeting of the Nonprescription Drugs Advisory Committee and the Drug Abuse Advisory Committee of the Food and Drug Administration. Rockville, MD. Retrieved from http://www.federalregister.gov/articles/1995/07/27/95-18448/cold-cough-allergy-bronchodilator-and-antiasthmatic-drug-products-for-over-the-counter-human-use.
7. Fiore, M. C., Bailey, W. C., Cohen, S. J., Dorfman, S. F., Goldstein, M. G., Gritz, E. R., et al. (2000). Treating tobacco use and dependence: Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service. Retrieved from http://www.surgeongeneral.gov/tobacco/treating_tobacco_use.pdf (last referenced on 6/22/11).
8. Fowler, J. S., Volkow, N. D., Wang, G. J., Pappas, N., Logan, J., MacGregor, R., et al. (1996). Inhibition of monoamine oxidase B in the brains of smokers. Nature, 379, 733-736. doi:10.1038/379733a0.
9. Fowler, J. S., Volkow, N. D., Wang, G. J., Pappas, N., Logan, J., Shea, C., et al. (1996). Brain monoamine oxidase A inhibition in cigarette smokers. Proceedings of the National Academy of Sciences of the United States of America, 93, 14065-14069. doi:10.1073/pnas.93.24.14065.
10. George, T. P., Vessicchio, J. C., Termine, A., Jatlow, P. I., Kosten, T. R., & O'Malley, S. S. (2003). A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biological Psychiatry, 53, 136-143. doi:10.1016/S0006-3223(02)01454-3.
11. Glaxo Smith Kline. (2009). Zyban (bupropion bydrochloride) sustained-release tablets. NDA 20-711/S-032/33 [Product Label]. Author.
12. Guy, W. (1976). ECDEU. Assessment manual for psychopharmacology: Publication no. ADM 76-336. Rockville, MD: U.S. Department of Health, Education and Welfare.
13. Heffner, J. L., Dawson, K., Jansern, J., Nolting, S. L., Winders-Barrett, S., & Anthenelli, R. M. (2007). Guide to clearing the air (modified). Unpublished treatment manual. University of Cincinnati.
14. Houtsmuller, E. J., Thornton, J. A., & Stitzer, M. L. (2002). Effects of selegiline (l-deprenyl) during smoking and short-term abstinence. Psychopharmacology, 163, 213-220. doi:10.1007/s00213-002-1152-9.
15. Hughes, J. R., Keely, J. P., Niaura, R. S., Ossip-Klein, D. J., Richmond, R. L., & Swan, G. E. (2003). Measures of abstinence in clinical trials: Issues and recommendations. Nicotine & Tobacco Research, 5, 13-25. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12745503 (last accessed on 6/22/11).
16. Killen, J. D., Fortmann, S. P., Murphy, G. M., Jr., Hayward, C., Fong, D., Lowenthal, K., et al. (2010). Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. Addiction, 105, 1660-1668. doi:10.1111/j.1360-0443.2010.03020.x.
17. Mendelson, J., Uemura, N., Harris, D., Nath, R. P., Fernandez, E., Jacob, P., III, et al. (2006). Human pharmacology of the methamphetamine stereoisomers. Clinical Pharmacology and Therapeutics, 80, 403-420. doi:10.1016/j.clpt.2006.06.013.
18. Riskind, J. H., Beck, A. T., Brown, G., & Steer, R. A. (1987). Taking the measure of anxiety and depression: Validity of the reconstructed Hamilton scales. Journal of Nervous and Mental Disease, 175, 474-479. doi:10.1097/00005053-198708000-00005.
19. Rohatagi, S., Barrett, J. S., DeWitt, K. E., & Morales, R. J. (1997). Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharmaceutics and Drug Disposition, 18, 567-584. doi:10.1002/(SICI)1099-081X(199710)18:7<567::AID-BDD49>3.0.CO;2-7.
20. Staley, J. K., Krishnan-Sarin, S., Cosgrove, K. P., Krantzler, E., Brohlich, E., Perry, E., et al. (2006). Human tobacco smokers in early abstinence have higher levels of β2* nicotinic acetylcholine receptors than non smokers. Journal of Neuroscience, 26, 8707-8714. doi:10.1523/JNEUROSCI.0546-06.2006.
21. Weinberger, A. H., Reutenauer, E. L., Jatlow, P. I., O'Malley, S. S., Potenza, M. N., & George, T. P. (2010). A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. Drug and Alcohol Dependence, 107, 188-195. doi:10.1016/j.drugalcdep.2009.10.009.